DOI: 10.1007/s00259-017-3678-4Pages: 1480-1489

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

1. Lund University, Department of Oncology and Pathology, Clinical Sciences

2. Skåne University Hospital, Department of Oncology

3. Lund University, Department of Medical Radiation Physics, Clinical Sciences

4. Sahlgrenska University Hospital, Department of Oncology

5. University of Gothenburg, Department of Radiation Physics

6. Sahlgrenska University Hospital, Department of Medical Physics and Biomedical Engineering

Correspondence to:
Anna Sundlöv
Tel: +46-46-175718




To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED).


Treatment was given with repeated cycles of 7.4 GBq 177Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging). All patients received treatment up to a renal BED of 27 ± 2 Gy (α/β = 2.6 Gy) (Step 1). Selected patients were offered further treatment up to a renal BED of 40 ± 2 Gy (Step 2). Renal function was followed by estimation and measurement of the glomerular filtration rate (GFR).


Fifty-one patients were included in the present analysis. Among the patients who received treatment as planned, the median number of cycles in Step 1 was 5 (range 3-7), and for those who completed Step 2 it was 7 (range 5-8); 73% were able to receive >4 cycles. Although GFR decreased in most patients after the completion of treatment, no grade 3-4 toxicity was observed. Patients with a reduced baseline GFR seemed to have an increased risk of GFR decline. Five patients received treatment in Step 2, none of whom exhibited a significant reduction in renal function.


Individualising PRRT using renal dosimetry seems feasible and safe and leads to an increased number of cycles in the majority of patients. The trial will continue as planned.

This article is freely available, click here to access the full text/PDF

  • Accepted: Mar 9, 2017
  • Online: Mar 22, 2017

Article Tools